Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DXCM NASDAQ:ILMN NASDAQ:ISRG NASDAQ:PODD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDXCMDexCom$67.78+2.7%$74.96$57.52▼$93.25$25.89B1.476.73 million shs5.95 million shsILMNIllumina$97.78+1.1%$98.47$68.70▼$156.66$14.86B1.41.72 million shs1.23 million shsISRGIntuitive Surgical$448.09+1.6%$460.50$425.00▼$616.00$158.07B1.612.47 million shs1.77 million shsPODDInsulet$315.49+0.7%$322.51$225.37▼$353.50$22.06B1.4679,618 shs465,016 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDXCMDexCom-0.50%-1.87%-17.99%-22.20%-3.77%ILMNIllumina-4.30%+1.80%-2.27%-0.78%-31.27%ISRGIntuitive Surgical-1.95%-1.41%-5.55%-16.51%-6.43%PODDInsulet+0.56%+1.53%-10.04%+5.38%+37.60%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDXCMDexCom$67.78+2.7%$74.96$57.52▼$93.25$25.89B1.476.73 million shs5.95 million shsILMNIllumina$97.78+1.1%$98.47$68.70▼$156.66$14.86B1.41.72 million shs1.23 million shsISRGIntuitive Surgical$448.09+1.6%$460.50$425.00▼$616.00$158.07B1.612.47 million shs1.77 million shsPODDInsulet$315.49+0.7%$322.51$225.37▼$353.50$22.06B1.4679,618 shs465,016 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDXCMDexCom-0.50%-1.87%-17.99%-22.20%-3.77%ILMNIllumina-4.30%+1.80%-2.27%-0.78%-31.27%ISRGIntuitive Surgical-1.95%-1.41%-5.55%-16.51%-6.43%PODDInsulet+0.56%+1.53%-10.04%+5.38%+37.60%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDXCMDexCom 2.87Moderate Buy$97.4243.73% UpsideILMNIllumina 2.15Hold$123.5626.36% UpsideISRGIntuitive Surgical 2.59Moderate Buy$589.4331.54% UpsidePODDInsulet 2.85Moderate Buy$346.839.93% UpsideCurrent Analyst Ratings BreakdownLatest ISRG, PODD, DXCM, and ILMN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025DXCMDexComWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)10/8/2025ILMNIlluminaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)10/8/2025ISRGIntuitive SurgicalWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)10/8/2025PODDInsuletWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)10/7/2025DXCMDexComCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$105.00 ➝ $85.0010/7/2025ILMNIlluminaEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$135.00 ➝ $132.0010/7/2025ISRGIntuitive SurgicalEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetIn-Line$535.00 ➝ $450.0010/3/2025PODDInsuletRothschild & Co RedburnSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$350.00 ➝ $370.0010/2/2025ILMNIlluminaBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetUnderweight$90.00 ➝ $95.0010/1/2025DXCMDexComThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$104.00 ➝ $89.0010/1/2025ISRGIntuitive SurgicalThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$621.00 ➝ $567.00(Data available from 10/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDXCMDexCom$4.03B6.59$2.31 per share29.38$5.38 per share12.60ILMNIllumina$4.37B3.44$4.74 per share20.61$14.96 per share6.54ISRGIntuitive Surgical$8.35B19.23$8.12 per share55.20$46.41 per share9.66PODDInsulet$2.07B10.72$4.47 per share70.65$17.27 per share18.27Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDXCMDexCom$576.20M$1.4447.0727.551.3813.29%30.41%10.08%10/30/2025 (Confirmed)ILMNIllumina-$1.22B$7.9012.3818.952.3329.36%28.93%10.74%11/3/2025 (Estimated)ISRGIntuitive Surgical$2.32B$7.1762.5058.734.6428.51%14.56%12.93%10/21/2025 (Estimated)PODDInsulet$418.30M$3.2995.8963.482.6010.01%23.78%9.30%11/6/2025 (Estimated)Latest ISRG, PODD, DXCM, and ILMN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/3/2025Q3 2025ILMNIllumina$1.16N/AN/AN/A$1.07 billionN/A10/30/2025Q3 2025DXCMDexCom$0.57N/AN/AN/A$1.18 billionN/A10/21/2025Q3 2025ISRGIntuitive Surgical$2.00N/AN/AN/A$2.41 billionN/A8/7/2025Q2 2025PODDInsulet$0.92$1.17+$0.25$0.32$612.31 million$649.10 million7/31/2025Q2 2025ILMNIllumina$1.02$1.19+$0.17$1.50$1.12 billion$1.06 billion7/30/2025Q2 2025DXCMDexCom$0.45$0.48+$0.03$0.45$1.13 billion$1.16 billion7/22/2025Q2 2025ISRGIntuitive Surgical$1.93$2.19+$0.26$1.81$2.35 billion$2.44 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDXCMDexComN/AN/AN/AN/AN/AILMNIlluminaN/AN/AN/AN/AN/AISRGIntuitive SurgicalN/AN/AN/AN/AN/APODDInsuletN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDXCMDexCom0.481.521.35ILMNIllumina0.661.811.41ISRGIntuitive SurgicalN/A5.174.18PODDInsulet0.642.261.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDXCMDexCom97.75%ILMNIllumina89.42%ISRGIntuitive Surgical83.64%PODDInsuletN/AInsider OwnershipCompanyInsider OwnershipDXCMDexCom0.32%ILMNIllumina2.60%ISRGIntuitive Surgical0.70%PODDInsulet0.39%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDXCMDexCom10,300392.15 million390.90 millionOptionableILMNIllumina9,030153.70 million149.70 millionOptionableISRGIntuitive Surgical15,638358.48 million355.97 millionOptionablePODDInsulet3,90070.39 million70.12 millionOptionableISRG, PODD, DXCM, and ILMN HeadlinesRecent News About These CompaniesTruist Securities Reiterates Buy Rating on Insulet (PODD) StockOctober 8 at 2:10 AM | insidermonkey.comAshley McEvoy explains how Insulet is using AI to advance diabetes careOctober 7 at 6:53 PM | drugdeliverybusiness.comDIs Insulet (PODD) a Solid Growth Stock? 3 Reasons to Think "Yes"October 7 at 1:45 PM | zacks.comInsulet Corporation $PODD Shares Sold by SGL Investment Advisors Inc.October 7 at 7:47 AM | marketbeat.comHighland Capital Management LLC Makes New Investment in Insulet Corporation $PODDOctober 6 at 4:45 AM | marketbeat.comInsulet (NASDAQ:PODD) & Canopy Growth (NASDAQ:CGC) Head to Head ContrastOctober 6 at 3:11 AM | americanbankingnews.comWe Like These Underlying Return On Capital Trends At Insulet (NASDAQ:PODD)October 5 at 12:52 PM | finance.yahoo.comInsulet Corporation $PODD Shares Acquired by ASR Vermogensbeheer N.V.October 5 at 3:47 AM | marketbeat.comRothschild & Co Redburn Forecasts Strong Price Appreciation for Insulet (NASDAQ:PODD) StockOctober 5 at 2:50 AM | americanbankingnews.comInsulet (NASDAQ:PODD) Given New $370.00 Price Target at Rothschild & Co RedburnOctober 4, 2025 | marketbeat.comFranklin Street Advisors Inc. NC Makes New Investment in Insulet Corporation $PODDOctober 4, 2025 | marketbeat.comLecap Asset Management Ltd. Takes Position in Insulet Corporation $PODDOctober 3, 2025 | marketbeat.comRobeco Institutional Asset Management B.V. Buys 119,786 Shares of Insulet Corporation $PODDOctober 3, 2025 | marketbeat.comInsulet Corporation $PODD Shares Purchased by Janney Montgomery Scott LLCOctober 3, 2025 | marketbeat.comInsulet (NASDAQ:PODD) Trading Down 3.4% After Analyst DowngradeOctober 3, 2025 | americanbankingnews.comAMI Asset Management Corp Has $50.88 Million Stock Position in Insulet Corporation $PODDOctober 2, 2025 | marketbeat.comInsulet Corporation $PODD Shares Sold by USA Financial FormulasOctober 2, 2025 | marketbeat.comLbp Am Sa Buys Shares of 15,629 Insulet Corporation $PODDOctober 2, 2025 | marketbeat.comInsulet (PODD) Receives a Buy from Canaccord GenuityOctober 1, 2025 | theglobeandmail.comCanaccord Genuity Raises Price Target on Insulet Corporation (PODD) to $399, Maintains Buy RatingOctober 1, 2025 | insidermonkey.comInsulet Corporation (PODD) Q2 Revenue Surges 32.9% to $649M, Raises Full-Year GuidanceOctober 1, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025The Fed Cut Rates: What Now for the S&P 500 and Equity Markets?By Thomas Hughes | September 18, 2025ISRG, TEAM, SFM Trade Well Below Highs With 30%+ UpsideBy Leo Miller | September 23, 2025Best Bang For Your Buck? 2 Bargain Stocks with 30%+ UpsideBy Nathan Reiff | September 14, 2025Is Intuitive Surgical the Hidden Winner in Healthcare’s Weakness?By Gabriel Osorio-Mazilli | October 1, 2025ISRG, PODD, DXCM, and ILMN Company DescriptionsDexCom NASDAQ:DXCM$67.78 +1.75 (+2.65%) Closing price 04:00 PM EasternExtended Trading$67.85 +0.07 (+0.10%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.Illumina NASDAQ:ILMN$97.78 +1.10 (+1.14%) Closing price 04:00 PM EasternExtended Trading$98.44 +0.66 (+0.67%) As of 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.Intuitive Surgical NASDAQ:ISRG$448.09 +7.15 (+1.62%) Closing price 04:00 PM EasternExtended Trading$450.11 +2.02 (+0.45%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. It has a collaboration agreement with FluoGuide A/S for head & neck cancer. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.Insulet NASDAQ:PODD$315.49 +2.04 (+0.65%) Closing price 04:00 PM EasternExtended Trading$316.24 +0.75 (+0.24%) As of 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Archer Aviation Stock Is Soaring—And What Comes Next Lithium Americas: Why This 31% Rally Is More Than Just a Headline Energy Transfer's New Growth Engine Ignites Investor Interest AMD Could Double From Here—Thanks to Its Blockbuster OpenAI Deal AMD and OpenAI: A Partnership That Just Redrew the AI Map EA’s $55 Billion Deal Spurs a Shake-Up in the Gaming Sector 3 Dividend Aristocrats to Buy Before Year’s End Falcon Flex Drives Growth as CrowdStrike Bets on AI Security Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
